It is no secret that pancreatic cancer is among the most deadly of malignancies. In Denmark alone, pancreatic ductal adenocarincoma - known as PDAC - is responsible for 1,200 deaths annually and fewer than one in five patients survives five years. Even as we make significant progress against treating one of oncology's toughest cancers, diagnosing PDAC with the right biomarkers and right test remains particularly elusive. Now more than ever, it is imperative we find the right patient population to treat and as early as possible.
In TIP-PDAC, we seek to achieve this by studying proteins in their native human tissue context, where the tumor is itself. That helps guide what signatures to look for in blood-based diagnostics, rather than going in blind. This approach will help us better understand and ultimately, diagnose disease earlier, where there is still hope for meaningful intervention.
Over the next 3 years, we will be building the world's largest dataset of human pancreatic cancer biology at the proteomic level, using that data to train predictive models of biology that will help us inform the next set of diagnostic and prognostic biomarkers in PDAC.
To guide this important work, Resolute Bio brings together some of the world's most renowned experts in pancreatic cancer:
Anirban Maitra, Director, Perlmutter Cancer Center at NYU Langone Health
— Hollingsworth Tony, Hunt Chair in Cancer Research and Associate Director of Basic Research at the Buffet Cancer Center at University of Nebraska Medical Center
— Paul Grandgenett, Director, UNMC Rapid Autopsy Program for Pancreas and Prostate Cancer
— Kristian Egebjerg, Board Member, UCPH Clinical Cancer Research Program, Rigshospitalet
Read more about the grant: https://lnkd.in/eSY_hkJG